This trial is no longer recruiting

Recruitment for this study has ended, so applications are closed. You can still read the trial details, or browse similar trials that are currently recruiting.

Not recruiting

Avacincaptad Pegol

Sponsor:

Astellas Pharma Global Development, Inc.

Code:

NCT06779773

Conditions

Geographic Atrophy

Macular Degeneration

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Avacincaptad pegol (ACP)

Study Details

Brief summary:

This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision.

Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy.

This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor have decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas).

People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for around 5 years.

Conditions

Geographic Atrophy

Macular Degeneration

Study ID

NCT06779773

Start date

Jan 22, 2025

Status verified date

Sep, 2026

Completion date

Oct 31, 2030

Anticipated

Primary completion date

Oct 31, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in 1 or both eyes
  • Patient with a decision to treat with intravitreal avacincaptad pegol (ACP) prior to enrollment
  • Patient willingness to complete the patient reported outcome (PRO).

Exclusion Criteria:

  • Patients who have any contraindication or are not eligible for treatment with ACP, including the following:

  • Active ocular or peri-ocular infection in either eye
  • Active, suspected intraocular inflammation in either eye
  • Hypersensitive to ACP or to any ingredient in the formulation
  • Patients currently participating in an investigational program with interventions outside of routine clinical practice.
  • Patients who have received ACP in the eye being considered for enrollment. Note: Patients who have received or are receiving ACP in the fellow eye at baseline are eligible to be included in the study.
  • Patients who have received any intravitreal complement inhibitor other than ACP in either eye. Note: Patients who have received an intravitreal complement inhibitor other than ACP in either eye and have completed the 90-day washout period are eligible to be included in the study.

Study Design

Enrollment

489 participants

Interventions and Outcome Measures

Arms

Izervay

Patients with geographic atrophy (GA) secondary to AMD who have made decision to begin treatment with Izervay

Interventions

Avacincaptad pegol (ACP)

intravitreal injection

Primary outcome measure

  • Number of ACP injections [ Time Frame: Up to 61 Months ]
  • Duration of treatment [ Time Frame: Up to 61 Months ]
  • Annual frequency of ACP injection [ Time Frame: Up to 61 Months ]
  • Reasons for discontinuation of treatment with ACP [ Time Frame: Up to 61 Months ]
  • Duration of the treatment interval [ Time Frame: Up to 61 Months ]
  • Site characteristics [ Time Frame: Day 1 ]
  • Characteristics of patients with geographic atrophy (GA) secondary to AMD beginning treatment with Izervay [ Time Frame: Day 1 ]

Central Contacts and Locations

More Information

Sponsor

Astellas Pharma Global Development, Inc.

Last update posted

Sep 22, 2026

Last verified

Sep, 2026

Keywords

  • Avacincaptad Pegol
  • IZERVAY™
  • Treatment patterns
  • Safety
  • Functional Outcomes

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-12. This information was provided to ClinicalTrials.gov by Astellas Pharma Global Development, Inc. on 2026-09-22. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.